1-Chloro-2-ethyl-3-methoxybenzene | 89032-12-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-Chloro-2-ethyl-3-methoxybenzene
• CAS: 89032-12-2
• 化学式: C₉H₁₁ClO
• 分子量: 170.63
• InChiKey: KZWWSKKYRGBJFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Triazine derivatives as inhibitors of phosphodiesterases
  申请人：Stange Hans

  公开号：US20100120762A1

  公开（公告）日：2010-05-13

  The invention relates to triazine derivatives of formula (I): which are inhibitors of phosphodiesterase 2 or 10, useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type 2 diabetes, metabolic syndrome, glucose intolerance, and pain.

  该发明涉及式（I）的三嗪衍生物，它们是磷酸二酯酶2或10的抑制剂，可用于治疗中枢神经系统疾病，如精神病，并且还可用于治疗例如肥胖症、2型糖尿病、代谢综合征、葡萄糖耐受不良和疼痛。
• DIFLUOROMETHYLENE COMPOUND
  申请人：SATO PHARMACEUTICAL CO., LTD.

  公开号：US20150191463A1

  公开（公告）日：2015-07-09

  The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R 1 is -Q 1 -A 1 or the like; R 2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W 1 , W 2 , W 3 and W 4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR 3 or the like.

  本发明涉及一种具有URAT1抑制活性的化合物，以及一种URAT1抑制剂、降低血尿酸水平的药物和含有该化合物的制剂。更具体地，本发明涉及一种由公式（I）表示的化合物： 其中，R1是-Q1-A1或类似物；R2是氢原子、卤原子、低碳基或类似物；W1、W2、W3和W4各自独立地是氮原子或可选取代基的甲烷基，或类似物；X和Y是单键、氧原子或类似物；Z是羟基、COOR3或类似物。
• PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS
  申请人：Sato Pharmaceutical Co., Ltd.

  公开号：EP3444238A2

  公开（公告）日：2019-02-20

  The invention refers to a method for producing a compound of the formula (1-6):

  本发明涉及一种生产式（1-6）化合物的方法：
• TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20210292299A1

  公开（公告）日：2021-09-23

  Provided herein are compounds of Formula (I′) or (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., proliferative diseases (e.g., cancers (e.g., carcinoma); lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, colorectal cancer)), metabolic disorders (e.g., diabetes), autoimmune diseases, and neurological diseases (e.g., Alzheimer's disease, gliosis, spinal cord injury)) in a subject, as well as for male contraception (e.g., reducing or inhibiting spermatogenesis, or reducing the rate of male fertility in a healthy fertile male subject). Provided are methods of inhibiting a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18) in a subject.
• PYRROLIDINE-FUSED HETEROCYCLES
  申请人：Erasca, Inc.

  公开号：US20210292330A1

  公开（公告）日：2021-09-23

  A compound of Formula (I) is provided: where the variables are defined herein.